JP Morgan | GenomeWeb

JP Morgan

The gene editing firm has sold all 5.9 million shares offered to the public as well as 885,000 shares in the fully exercised over-allotment option to the underwriters.

Westin St. Francis Hotel, San Francisco, site of the JP Morgan Healthcare Conference

Executives from Luminex, Exact Sciences, T2 Biosystems, and Singulex provided updates on their companies' businesses on the final day of the conference.

The chemistry will be single-molecule, based on hybridization, and will not require amplification, enzymes, or library prep, the firm said.

Executives from Thermo Fisher Scientific, Qiagen, Danaher, Counsyl, Human Longevity, and Adaptive Biotechnologies provided business updates to conference goers.

Executives from the sequencing tech firms provided attendees with an update on recently launched products and platforms, and future technology developments.

Executives from 23andMe, Myriad Genetics, Genomic Health, and Alere provided updates on their companies at the JP Morgan Healthcare Conference in San Francisco.

The company also announced the Infinium XT genotyping array for analyzing large sample numbers, and provided preliminary earnings for Q4 and full-year 2015.

The amendment to a 2013 debt financing agreement will increase revolving commitments to $1.3 billion, extend maturity of loans, and adjust interest rates and fees.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Citing expected organic growth and a continuing ramp up of QIAsymphony, investment bank JP Morgan today upgraded Qiagen to Overweight.

Pages

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.